JPMorgan Chase & Co. Cuts Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target to $800.00

Regeneron Pharmaceuticals (NASDAQ:REGN) had its target price trimmed by JPMorgan Chase & Co. from $950.00 to $800.00 in a report issued on Monday morning,Benzinga reports. The firm currently has an overweight rating on the biopharmaceutical company’s stock.

Several other equities research analysts have also recently weighed in on REGN. Wall Street Zen cut shares of Regeneron Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Thursday, May 1st. Canaccord Genuity Group upgraded shares of Regeneron Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, April 22nd. Morgan Stanley decreased their price objective on shares of Regeneron Pharmaceuticals from $958.00 to $755.00 and set an “overweight” rating for the company in a research report on Monday, June 2nd. BMO Capital Markets decreased their price objective on shares of Regeneron Pharmaceuticals from $800.00 to $600.00 and set an “outperform” rating for the company in a research report on Monday, June 2nd. Finally, Royal Bank of Canada cut shares of Regeneron Pharmaceuticals from a “moderate buy” rating to a “hold” rating and set a $662.00 price objective for the company. in a research report on Friday, May 30th. One investment analyst has rated the stock with a sell rating, six have issued a hold rating, seventeen have assigned a buy rating and three have issued a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $836.48.

Regeneron Pharmaceuticals Trading Down 0.9%

Shares of NASDAQ REGN opened at $518.60 on Monday. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.95 and a current ratio of 4.73. Regeneron Pharmaceuticals has a 52-week low of $476.49 and a 52-week high of $1,211.20. The firm has a 50 day moving average price of $564.76 and a two-hundred day moving average price of $653.10. The stock has a market cap of $55.99 billion, a P/E ratio of 13.55, a price-to-earnings-growth ratio of 2.34 and a beta of 0.31.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings results on Tuesday, April 29th. The biopharmaceutical company reported $8.22 earnings per share (EPS) for the quarter, missing the consensus estimate of $8.83 by ($0.61). Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. The business had revenue of $3.03 billion during the quarter, compared to analyst estimates of $3.40 billion. During the same quarter last year, the company posted $9.55 earnings per share. The company’s revenue was down 3.7% compared to the same quarter last year. As a group, equities analysts forecast that Regeneron Pharmaceuticals will post 35.92 EPS for the current year.

Regeneron Pharmaceuticals Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Friday, June 6th. Shareholders of record on Tuesday, May 20th were paid a $0.88 dividend. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.68%. The ex-dividend date of this dividend was Tuesday, May 20th. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is 8.96%.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in REGN. Pinney & Scofield Inc. bought a new position in shares of Regeneron Pharmaceuticals in the fourth quarter valued at $25,000. E Fund Management Hong Kong Co. Ltd. lifted its position in shares of Regeneron Pharmaceuticals by 344.4% during the first quarter. E Fund Management Hong Kong Co. Ltd. now owns 40 shares of the biopharmaceutical company’s stock valued at $25,000 after purchasing an additional 31 shares in the last quarter. Activest Wealth Management lifted its position in shares of Regeneron Pharmaceuticals by 110.5% during the first quarter. Activest Wealth Management now owns 40 shares of the biopharmaceutical company’s stock valued at $25,000 after purchasing an additional 21 shares in the last quarter. Costello Asset Management INC bought a new position in shares of Regeneron Pharmaceuticals during the first quarter valued at about $27,000. Finally, Saudi Central Bank bought a new position in shares of Regeneron Pharmaceuticals during the first quarter valued at about $27,000. 83.31% of the stock is owned by institutional investors.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.